Growth hormone deficiency historical perspective: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Growth hormone deficiency}}
{{Growth hormone deficiency}}
{{CMG}}; {{AE}}  
{{CMG}}; {{AE}} {{MAD}}


==Overview==
==Overview==
Line 16: Line 16:
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WH}}
{{WS}}

Revision as of 18:09, 8 August 2017

Growth hormone deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Growth hormone deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Growth hormone deficiency historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Growth hormone deficiency historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Growth hormone deficiency historical perspective

CDC on Growth hormone deficiency historical perspective

Growth hormone deficiency historical perspective in the news

Blogs on Growth hormone deficiency historical perspective

Directions to Hospitals Treating Growth hormone deficiency

Risk calculators and risk factors for Growth hormone deficiency historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]

Overview

In the mid-1940s, bovine GH has been purified for the first time then, growth hormone was isolated from the human pituitary gland in 1956. 7700 children in the United States and 27,000 children worldwide were given GH extracted from human pituitary glands. In 1981, Genentech developed the first recombinant human GH.

Historical Perspective

  • In the mid-1940s, bovine GH has been purified by Li and Evans at the University of California, Berkeley, and Fishman at Yale.[1]
  • In 1956, growth hormone was isolated from the human pituitary gland by both Li and Papkoff, in California.
  • Between 1963 and 1985, 7700 children in the United States and 27,000 children worldwide were given GH extracted from human pituitary glands to treat severe Growth hormone deficiency.[2]
  • In 1985, US Food and Drug Administration (US FDA) received reports of four young adults in the United States with Creuzfeldt Jacob Disease (CJD), who had been treated with GH and treatment with GH extracts has been stopped completely.[3]
  • in 1981, Genentech (San Francisco, California) developed the first recombinant human GH (rhGH) by DNA cloning and was introduced in the United States in 1985 for the therapy of severe childhood GHD. [4]
  • List of indications for GH use in non–GH-deficient children and adults have increased with time.[5]

References

  1. Frasier SD (1997). "The not-so-good old days: working with pituitary growth hormone in North America, 1956 to 1985". J Pediatr. 131 (1 Pt 2): S1–4. PMID 9255217.
  2. Franklin SL, Geffner ME (2009). "Growth hormone: the expansion of available products and indications". Endocrinol Metab Clin North Am. 38 (3): 587–611. doi:10.1016/j.ecl.2009.06.006. PMID 19717006.
  3. "Degenerative neurologic disease in patients formerly treated with human growth hormone. Report of the Committee on Growth Hormone Use of the Lawson Wilkins Pediatric Endocrine Society, May 1985". J Pediatr. 107 (1): 10–2. 1985. PMID 3891943.
  4. Flodh H (1986). "Human growth hormone produced with recombinant DNA technology: development and production". Acta Paediatr Scand Suppl. 325: 1–9. PMID 3296632.
  5. Takeda A, Cooper K, Bird A, Baxter L, Frampton GK, Gospodarevskaya E; et al. (2010). "Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation". Health Technol Assess. 14 (42): 1–209, iii–iv. doi:10.3310/hta14420. PMID 20849734.